A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Inclusion Criteria: * Patient has a diagnosis of Acromegaly * Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline * Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country * Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study Exclusion Criteria: * Patients with known significant valve abnormalities prior to treatment with either lanreotide or octreotide * Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months * Patients who have received treatment with a GH antagonist for more than 3 months * Patients who have had heart valve replacement therapy